at://
/
app.bsky.feed.post
/
3ml5djsmr2c2u
sign in
All
4
Record
2
Post
1
PostEmbed
1
Post
by @danabra.mov
PostEmbed
by @danabra.mov
Record
by @jimpick.com
Record
by @atsui.org
+ new component
Post
Noxopharm (ASX:NOX) advances US FDA pre-IND strategy for SOF-SKN™, targeting $3.3B+ autoimmune skin disease market. Engages global CRO Novotech to boost regulatory and commercial potential. #Biotech #DrugDevelopment bit.ly/49dSDyk
1mo
bit.ly
